EBS Technologies | Updates
This investment carries considerable risks and may lead to a complete loss of the capital invested. More
By Team EBS Technologies

EBS Business Model Ensures Continuous Revenue Stream

Public
Public
 

 

Dear Companists,

A Companist asked us the following question:

"If EBS does not sell its products to hospitals, how does EBS make money?"

The answer is very simple: by generating a revenue stream through patients treated.

Having recently explained why a medical technology company such as EBS Technologies primarily focuses on an exit and why an exit is more likely in our industry than in others (see our last update), we now want to explain our business model to you.

 

 

 

Usage Fee per Patient Treated

 

In the EBS business model, each therapy center is a source of revenue because EBS charges a usage fee of 1,850 euros per patient treated. Thus, once a NEXT WAVE™ system has been installed, it generates a constant increase in revenue from the first day onward. Each additional center increases this revenue stream.

 

As a result, even a single NEXT WAVE™ system can generate much more value for the company than a single device sold ever could.

 

 

 

The NEXT WAVE™ System in Use

 

No Obstacles to Investment for Hospitals

The EBS business model does not require any system to be sold. Therefore, lengthy negotiations over investments within hospitals, long and unpaid trial periods, and high sales costs caused by numerous visits are no longer necessary. In fact, all these efforts do not even guarantee that a system is actually sold in the end. The EBS approach is much easier: EBS provides select and competent therapy centers with the NEXT WAVE™ system and trains the centers' employees. Thus, there are no obstacles to investment for hospitals, but long-term chances of attracting many additional patients through such a therapy method are high. Currently, this is happening only in a few select centers, but their number will keep increasing. Also, we will expand our network of therapy centers from Germany to Europe and to the U.S. later.

 

 

Our most important KPI is the total number of patients treated in the therapy centers. The number of therapy centers, on the other hand, is slightly less important because centers in central locations may use several NEXT WAVE™ systems simultaneously and thus reach the same capacity as a higher number of centers would.

 

Win-Win-Win Situation for Hospitals, EBS, and Patients

Because of our step-by-step approach, we can keep the amount of work and the capital required moderate at all times. Since all centers – just like EBS – make money when they use the system, they have a vital interest in treating patients with it on a regular basis. This benefits both EBS and the hospitals. And most of all, this is beneficial for patients because the therapy method would simply not exist if there were no incentive to offer it.

It is only a matter of time before other companies adopt this sustainable growth model that is ideally suitable for innovative technologies.

Best regards,
EBS Technologies



Comments

Only registered Companists can comment. Please log in to leave a comment.

NOTE:

Investments in crowdfunding projects offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, these investments are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by splitting their investment amount between crowdfunding campaigns rather than investing all of it in one crowdfunding campaign. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the Companists are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the Companists – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, crowdfunding investments are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

684

Companists

258,825 €

Invested

3.67 %

Share offered

Contact Details
EBS Technologies GmbH
Neuendorfstraße 20 b
16761 Hennigsdorf
Germany

Email: invest@ebstech.de
Website: www.ebstech.de
Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used.

Follow us

Contact Us
Your contact for all questions about investing on Companisto:
Andreas Riedel
Investor Relations

Toll-free phone number for investors

0800 - 100 26 70 (DE)
0800 - 10 02 67 (AT)
0800 - 10 02 67 (CH)

Service hours Mo-Fr 9 a.m.- 7 p.m.

Companisto GmbH
Köpenicker Str. 154
10997 Berlin
TÜV geprüftes Online-Portal | Companisto
Source: Own research. Based on data from the German Private Equity and Venture Capital Association - BVK, among others.
Investor Support